Close
What would you like to look for?
Site search
Search filters

Inositec AG acquired by Vifor Pharma

Vifor Pharma acquires Zurich-based Inositec AG. Inositec develops first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders.

Anjarium Biosciences Raises CHF 55.5m (USD 61m) Series A Financing

Anjarium Biosciences AG, a biotech company in Schlieren (ZH) focused on creating and delivering a new class of non-viral gene therapies has closed a CHF55.5m Series A Financing.

EGO Movement and TVS Motor agree on a strategic partnership

The fast-growing Swiss e-mobility company EGO Movement (the GO AG) has agreed on a long-term strategic partnership with the leading Indian mobility group TVS Motor.

Novaremed acquires Metys Pharmaceuticals

Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals.

Combioxin enters worldwide license agreement with Eagle Pharmaceuticals

ombioxin SA, a clinical-stage biotechnology company based in Epalinges, Switzerland, entered into a worldwide licensing agreement with Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX), a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA.

Novartis acquires option to acquire Zurich-based startup Cellerys

Novartis has signed a collaboration agreement and an option to acquire Cellerys. The Zurich-based startup is researching an innovative therapy to combat multiple sclerosis (MS).

DomoSafety SA closes a Serie B financing round

DomoSafety SA, a leading company in the digital health segment, announced the successful closing of its Series B financing round.

Faveeo SA closes a Series B financing round

Faveeo SA, a Swiss start-up, announced the successful closing of its Series B financing round.

Haya Therapeutics completes CHF 18m Seed Financing Round

HAYA Therapeutics SA announced the successful closing of its CHF 18m seed round.

Oculis closes an oversubscribed USD 57m Series C financing round

Oculis S.A., a late-stage biopharmaceutical company, focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, has closed an oversubscribed USD 57m Series C financing round.

You are currently offline. Some pages or content may fail to load.